root cause – Page 105

Backing delamination after lamination – inspection finding risk

Investigating Backing Delamination Post-Lamination in Transdermal Patches Backing delamination after lamination is a significant concern in the manufacturing of transdermal patches. This issue can lead to product recalls, regulatory scrutiny,…

Edge lifting observed during storage – CAPA documentation failure

Investigating Edge Lifting in Transdermal Patches During Storage: A CAPA Approach In the world of pharmaceutical manufacturing, ensuring product integrity through every stage of production and storage is essential. One…

Patch curling during patch manufacturing – CAPA documentation failure

Understanding and Investigating Patch Curling in Transdermal Patch Manufacturing In today’s fast-paced pharmaceutical environment, the occurrence of manufacturing defects, such as patch curling during patch manufacturing, poses a significant challenge.…

Adhesion failure during storage – inspection finding risk

Investigating Adhesion Failures in Transdermal Patches During Storage Adhesion failure in transdermal patches during storage can pose significant risks to product quality and patient safety. Such failures may lead to…

Edge lifting observed during storage – process vs material root cause

Investigating Edge Lifting During Storage: A Comprehensive Approach to Root Cause Analysis In the pharmaceutical manufacturing industry, maintaining product quality during storage is critical. One common issue that arises is…

Capsule puncture failure during stability testing – regulatory expectation mismatch

Investigating Capsule Puncture Failures in Stability Testing: Addressing Regulatory Expectations Capsule puncture failures during stability testing present significant challenges in pharmaceutical manufacturing. These failures can lead to batches being deemed…

Delivered dose uniformity failure during inspection readiness – regulatory expectation mismatch

Addressing Delivered Dose Uniformity Failures During Inspection Preparedness In the pharmaceutical manufacturing sector, ensuring delivered dose uniformity (DDU) is critical for compliance and product efficacy, especially for dry powder inhalers…

Powder flow issue after device change – device vs formulation investigation

Investigating Powder Flow Issues Following Device Changes in DPI Manufacturing In the world of pharmaceutical manufacturing, deviations such as a powder flow issue after a device change can significantly impact…

Delivered dose uniformity failure during DPI filling – device vs formulation investigation

Investigating Delivered Dose Uniformity Failures During DPI Filling: A Practical Approach In the pharmaceutical manufacturing landscape, the integrity of drug delivery systems, such as Dry Powder Inhalers (DPIs), is critical.…

Fine particle fraction drift during stability testing – CAPA control strategy gap

Addressing Fine Particle Fraction Drift in Stability Testing: A Comprehensive Investigation Approach In the pharmaceutical industry, ensuring product quality during stability testing is crucial, particularly for inhalation therapies such as…

Moisture ingress detected during DPI filling – CAPA control strategy gap

Investigation into Moisture Ingress Detected during DPI Filling: Addressing CAPA Control Strategy Gaps In pharmaceutical manufacturing, especially in the production of Dry Powder Inhalers (DPIs), maintaining the integrity of the…

Capsule puncture failure during DPI filling – device vs formulation investigation

Investigation into Capsule Puncture Failures During DPI Filling: A Comprehensive Guide Capsule puncture failures during the filling of dry powder inhalers (DPIs) pose significant challenges in pharmaceutical manufacturing, affecting product…